Drug intelligence / Profile preview

Oryctolagus cuniculus skin

Development stage: Unknown
Lead developer: Greer Laboratories
Modality: Recombinant Proteins and Enzymes
Administration: Intradermal, Percutaneous, Topical

Overview

Oryctolagus cuniculus skin refers to an extract derived from the skin of the European rabbit (Oryctolagus cuniculus). It is primarily used in allergy testing as a source of allergenic proteins to diagnose sensitivities in humans. The extract may contain various biologically active substances, and there are reports of its use in preparing drugs and health foods, particularly when the rabbit has been vaccinated with vaccinia virus to induce inflammation and increase biological activity. The mechanism of action for its use in allergy testing is based on eliciting an immune response upon exposure to specific allergens present in rabbit skin extracts[1][6].

Other names: rabbit skin

Beyond the preview

Go deeper on Oryctolagus cuniculus skin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Oryctolagus cuniculus skin.

Explore the full profile